BIMI International Medical, a leading healthcare products company, today announced its financial results for the quarter ended September 30. BIMI soars 69% in the pre-market trading today. It’s selling its single stock for $1.11. The company’s revenue for the three months ended on September 30, rose to $13,777,492 from $3,091,070 in the previous year. Gross profit for the period also increased to $2,29,109 from $1,271,278 in the previous year. For the third quarter of 2021, the company’s revenue grew by 12%, primarily due to the increase in sales of pharmaceuticals. During the same period, the operations of recently acquired hospitals contributed to the company’s growth. For the three-month period ended September 30, 2021, revenues were $13,777.49 million, and for the nine-month period ended September 30, 2021, revenues were $7,315,449.
The revenue of the pharmaceutical segment from the third quarter of 2017 to the third quarter of 2020 was $8,483,024. For the nine months ended September 30 of the same year, the revenue of the segment was $14,978,955. The revenue of the medical devices segment from 2020, to September 30, 2021, was $669,276. For the nine months ended on the same period, the segment’s revenue was $2,524,017. The medical services segment’s revenue was $6,694,510 for the nine months ended September 2021.